Revenue from contracts with customers |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disclosure of disaggregation of revenue from contracts with customers [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue from contracts with customers |
Note 4 — Revenue from contracts with customers Disaggregation of revenue from contracts with customers The principal revenue activities of the Company for the years ended March 31, 2024, 2023 and 2022 were as follows:
Revenues were $156,419 for the year ended March 31, 2024 which consisted of sales of test kits to two customers. Revenues were $8,561 for the year ended March 31, 2023 which consisted of sales of test kits to one customer. There was no revenue for the year ended March 31, 2022. Accounting policies and significant judgments Management does not consider there to be any significant judgments or estimates in the revenue recognition for the years ended March 31, 2024 and 2023. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for revenue from contracts with customers. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|